EFHD1

Summary

EFHD1 (EF-hand domain family member D1, HGNC:29556) is a protein-coding gene on chromosome 2q37.1, encoding EF-hand domain-containing protein D1 (Q9BUP0). Acts as a calcium sensor for mitochondrial flash (mitoflash) activation, an event characterized by stochastic bursts of superoxide production.

This gene encodes a member of the EF-hand super family of calcium binding proteins, which are involved in a variety of cellular processes including mitosis, synaptic transmission, and cytoskeletal rearrangement. The protein encoded by this gene is composed of an N-terminal disordered region, proline-rich elements, two EF-hands, and a C-terminal coiled-coil domain. This protein has been shown to associate with the mitochondrial inner membrane, and in HeLa cells, acts as a novel mitochondrial calcium ion sensor for mitochondrial flash activation. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 80303 — RefSeq curated summary.

At a glance

• GWAS associations: 17
• Clinical variants (ClinVar): 37 total
• MANE Select transcript: NM_025202

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29556
Approved symbol	EFHD1
Name	EF-hand domain family member D1
Location	2q37.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ13612
Ensembl gene	ENSG00000115468
Ensembl biotype	protein_coding
OMIM	611617
Entrez	80303

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 7 protein_coding, 1 nonsense_mediated_decay

ENST00000264059, ENST00000409613, ENST00000409708, ENST00000410095, ENST00000427698, ENST00000442845, ENST00000865005, ENST00000865006

RefSeq mRNA: 3 — MANE Select: NM_025202 NM_001243252, NM_001308395, NM_025202

CCDS: CCDS2497, CCDS58755, CCDS82580

Canonical transcript exons

ENST00000264059 — 4 exons

Exon	Start	End
ENSE00000965612	232681585	232682776
ENSE00001029714	232633604	232634006
ENSE00003474969	232662802	232662949
ENSE00003474989	232672309	232672443

Expression profiles

Bgee: expression breadth ubiquitous, 270 present calls, max score 99.55.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 30.3562 / max 1154.6047, expressed in 932 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
26003	27.2236	917
26000	1.2823	273
25999	0.6963	182
26004	0.6634	328
26002	0.2591	72
26006	0.1377	72
26001	0.0583	27
25998	0.0354	20

Top tissues by expression

294 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
inferior olivary complex	UBERON:0002127	99.55	gold quality
dorsal motor nucleus of vagus nerve	UBERON:0002870	99.27	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	99.19	gold quality
popliteal artery	UBERON:0002250	99.01	gold quality
tibial artery	UBERON:0007610	99.01	gold quality
spinal cord	UBERON:0002240	98.90	gold quality
right coronary artery	UBERON:0001625	98.86	gold quality
aorta	UBERON:0000947	98.84	gold quality
ascending aorta	UBERON:0001496	98.75	gold quality
thoracic aorta	UBERON:0001515	98.74	gold quality
descending thoracic aorta	UBERON:0002345	98.34	gold quality
cranial nerve II	UBERON:0000941	98.32	gold quality
substantia nigra	UBERON:0002038	98.32	gold quality
medial globus pallidus	UBERON:0002477	98.30	gold quality
globus pallidus	UBERON:0001875	98.28	gold quality
midbrain	UBERON:0001891	98.19	gold quality
inferior vagus X ganglion	UBERON:0005363	98.16	gold quality
left coronary artery	UBERON:0001626	98.02	gold quality
metanephros cortex	UBERON:0010533	97.98	gold quality
renal medulla	UBERON:0000362	97.93	gold quality
CA1 field of hippocampus	UBERON:0003881	97.91	gold quality
adult mammalian kidney	UBERON:0000082	97.83	gold quality
coronary artery	UBERON:0001621	97.78	gold quality
lateral globus pallidus	UBERON:0002476	97.67	gold quality
subthalamic nucleus	UBERON:0001906	97.66	gold quality
amygdala	UBERON:0001876	97.65	gold quality
putamen	UBERON:0001874	97.62	gold quality
hypothalamus	UBERON:0001898	97.40	gold quality
substantia nigra pars reticulata	UBERON:0001966	97.39	gold quality
blood vessel layer	UBERON:0004797	97.38	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 8.

Experiment	Marker?	Max mean expression
E-MTAB-10885	yes	550.46
E-MTAB-3929	yes	186.56
E-MTAB-10287	yes	51.11
E-CURD-119	yes	47.49
E-GEOD-135922	yes	30.94
E-GEOD-84465	yes	10.06
E-GEOD-134144	yes	8.43
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): HNF4A

miRNA regulators (miRDB)

49 targeting EFHD1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-4517	99.76	69.19	1867
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-4524A-3P	99.72	66.85	2406
HSA-MIR-3714	99.71	70.74	2671
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-7-5P	99.67	70.53	1809
HSA-MIR-651-5P	99.64	68.49	1104
HSA-MIR-6716-5P	99.56	68.62	1244
HSA-MIR-7106-5P	99.53	67.47	3574
HSA-MIR-3123	99.47	67.15	2693
HSA-MIR-1275	99.47	67.90	2749
HSA-MIR-4316	99.37	65.75	1360
HSA-MIR-5683	99.36	68.59	2083
HSA-MIR-4311	99.31	70.47	3041
HSA-MIR-149-5P	99.25	67.16	1315
HSA-MIR-491-5P	99.13	65.98	1468
HSA-MIR-935	98.82	69.36	1072
HSA-MIR-16-1-3P	98.70	69.23	1538
HSA-MIR-6840-3P	98.68	65.95	1923
HSA-MIR-2467-3P	98.65	67.18	1969

Literature-anchored findings (GeneRIF, showing 4)

• Cloning of novel mouse genes associated with neuronal function, including Efhd1. (PMID:12270117)
• detection of methylation of PPP1R3C alone or in combination with EFHD1 in plasma DNA showed high sensitivity and specificity in CRC detection, and may be useful detection method for CRC, especially for early-stage CRCs. (PMID:24861485)
• EFHD1 functions as a novel mitochondrial Ca(2+) sensor underlying Ca(2+)-dependent activation of mitoflashes (PMID:26975899)
• EFHD1, a novel mitochondrial regulator of tumor metastasis in clear cell renal cell carcinoma. (PMID:36747492)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	efhd1	ENSDARG00000043446
mus_musculus	Efhd1	ENSMUSG00000026255
rattus_norvegicus	Efhd1	ENSRNOG00000015596
drosophila_melanogaster	Swip-1	FBGN0032731
drosophila_melanogaster	CG14861	FBGN0038280
caenorhabditis_elegans		WBGENE00012980

Paralogs (1): EFHD2 (ENSG00000142634)

Protein

Protein identifiers

EF-hand domain-containing protein D1 — Q9BUP0 (reviewed: Q9BUP0)

Alternative names: EF-hand domain-containing protein 1, Swiprosin-2

All UniProt accessions (4): C9JTV4, Q9BUP0, H7C0I0, Q8WYH2

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a calcium sensor for mitochondrial flash (mitoflash) activation, an event characterized by stochastic bursts of superoxide production. May play a role in neuronal differentiation.

Subcellular location. Mitochondrion inner membrane.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BUP0-1	1	yes
Q9BUP0-2	2

RefSeq proteins (3): NP_001230181, NP_001295324, NP_079478* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002048	EF_hand_dom	Domain
IPR011992	EF-hand-dom_pair	Homologous_superfamily
IPR040365	EFHD1/2	Family

Pfam: PF13499

UniProt features (20 total): binding site 8, mutagenesis site 4, domain 2, chain 1, modified residue 1, splice variant 1, sequence variant 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BUP0-F1	78.10	0.25

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (8): 143; 145; 150; 103; 107; 114; 139; 141

Post-translational modifications (1): 201

Mutagenesis-validated functional residues (4):

Position	Phenotype
103	in mtefhd1; abolished ability to enhance mitoflash activity; when associated with k-114; a-139 and k-150.
114	in mtefhd1; abolished ability to enhance mitoflash activity; when associated with a-103; a-139 and k-150.
139	in mtefhd1; abolished ability to enhance mitoflash activity; when associated with a-103; k-114 and k-150.
150	in mtefhd1; abolished ability to enhance mitoflash activity; when associated with a-103; k-114 and a-139.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 174 (showing top): PAX4_01, PEREZ_TP63_TARGETS, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GOBP_NEUROGENESIS, GOBP_HYPEROSMOTIC_RESPONSE, LUCAS_HNF4A_TARGETS_UP, SRF_Q5_01, SRF_C, CREIGHTON_ENDOCRINE_THERAPY_RESISTANCE_1, RAMALHO_STEMNESS_DN, GOBP_RESPONSE_TO_SALT_STRESS, TCF11_01, GOBP_REGULATION_OF_RESPONSE_TO_STRESS, YAO_TEMPORAL_RESPONSE_TO_PROGESTERONE_CLUSTER_6

GO Biological Process (2): neuron projection development (GO:0031175), regulation of cellular hyperosmotic salinity response (GO:1900069)

GO Molecular Function (4): calcium ion binding (GO:0005509), calcium ion sensor activity (GO:0061891), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (3): mitochondrion (GO:0005739), mitochondrial inner membrane (GO:0005743), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
neuron development	1
plasma membrane bounded cell projection organization	1
cellular hyperosmotic salinity response	1
regulation of cellular response to osmotic stress	1
regulation of response to salt stress	1
metal ion binding	1
calcium ion binding	1
metal ion sensor activity	1
binding	1
cation binding	1
cytoplasm	1
intracellular membrane-bounded organelle	1
organelle inner membrane	1
mitochondrial membrane	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1010 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EFHD1	RHAG	Q02094	800
EFHD1	ERMN	Q8TAM6	474
EFHD1	SLC24A1	O60721	447
EFHD1	TEX44	Q53QW1	421
EFHD1	RRH	O14718	398
EFHD1	OPN4	Q9UHM6	380
EFHD1	RHO	P08100	379
EFHD1	OPN3	Q9H1Y3	378
EFHD1	OPN1SW	P03999	361
EFHD1	ITSN1	Q15811	359
EFHD1	OPN5	Q6U736	348
EFHD1	TRIP12	Q14669	347
EFHD1	EPS8L1	Q8TE68	329
EFHD1	CYP27C1	Q4G0S4	323
EFHD1	EFCC1	Q9HA90	320

IntAct

62 interactions, top by confidence:

A	B	Type	Score
EXOC6B	EXOC5	psi-mi:“MI:0914”(association)	0.790
CEP164	TTBK2	psi-mi:“MI:0914”(association)	0.680
ANXA9	PPL	psi-mi:“MI:0914”(association)	0.660
CAPZA2	CNOT1	psi-mi:“MI:0914”(association)	0.640
G2E3	SPECC1L	psi-mi:“MI:0914”(association)	0.560
ZIC2	EFHD1	psi-mi:“MI:0915”(physical association)	0.560
MAS1	POTEF	psi-mi:“MI:0914”(association)	0.530
FSD1	UBFD1	psi-mi:“MI:0914”(association)	0.530
DUSP10	ACTB	psi-mi:“MI:0914”(association)	0.530
OXNAD1	HSPD1	psi-mi:“MI:0914”(association)	0.530
PPIAL4G	ACTB	psi-mi:“MI:0914”(association)	0.530
NDNF	EFHD1	psi-mi:“MI:0915”(physical association)	0.400
EFHD1	PSEN1	psi-mi:“MI:0915”(physical association)	0.370
NS1	SAC3D1	psi-mi:“MI:0914”(association)	0.350
PB2	HAX1	psi-mi:“MI:0914”(association)	0.350
ESR1	ESYT2	psi-mi:“MI:0914”(association)	0.350
PPIAL4G	PPIAL4D	psi-mi:“MI:0914”(association)	0.350
FOXP2	DUSP14	psi-mi:“MI:0914”(association)	0.350
CPLX4	HSPA8	psi-mi:“MI:0914”(association)	0.350
S100A8	SMTNL2	psi-mi:“MI:0914”(association)	0.350
OCIAD1	NDUFS8	psi-mi:“MI:0914”(association)	0.350
PHYHIPL	ATP5F1B	psi-mi:“MI:0914”(association)	0.350
ADCK2	SLC25A5	psi-mi:“MI:0914”(association)	0.350
PTPMT1	NDUFAB1	psi-mi:“MI:0914”(association)	0.350
CTBP1	TAF15	psi-mi:“MI:0914”(association)	0.350

BioGRID (95): EFHD1 (Affinity Capture-MS), EFHD1 (Affinity Capture-MS), EFHD1 (Affinity Capture-MS), EFHD1 (Affinity Capture-MS), EFHD1 (Affinity Capture-MS), EFHD1 (Affinity Capture-MS), EFHD1 (Affinity Capture-MS), EFHD1 (Affinity Capture-MS), EFHD1 (Affinity Capture-MS), EFHD1 (Affinity Capture-MS), EFHD1 (Affinity Capture-RNA), EFHD1 (Affinity Capture-MS), TCHH (Affinity Capture-MS), KRT33B (Affinity Capture-MS), EFHD1 (Affinity Capture-MS)

ESM2 similar proteins: A0A8I6A2H6, A2VEI2, A4IG32, A4IHK8, A5D7A0, D2HZB0, D4A1F2, E9Q4Z2, F1MF74, O00763, O08874, O14795, O94851, P23092, Q05AA6, Q08BI9, Q13474, Q17QM6, Q3TWN3, Q4FZY0, Q4KUS2, Q4V8B2, Q5E9V1, Q5R9G1, Q5RDI4, Q5U2P1, Q5ZJT0, Q62768, Q62769, Q69ZT9, Q6DFA1, Q86XE3, Q8BHD4, Q8BML1, Q8IWE4, Q8K0V2, Q8WN03, Q96C19, Q9BQI0, Q9BUP0

Diamond homologs: A5D7A0, O70200, O81092, P04112, P04113, P05944, P29289, P54680, P55008, P55009, P81076, Q09011, Q11083, Q17QM6, Q32LE3, Q4FZY0, Q54QX0, Q5RDI4, Q5TM25, Q8VWY7, Q96C19, Q9AWK2, Q9BDK2, Q9BQI0, Q9BUP0, Q9D4J1, Q9D8Y0, Q9EQX4, Q9SRP7, Q9VJ26, O60041, O96102, P06787, P14533, P25071, P80322, Q09665, Q12798, Q9XZP2, A4IF97

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

37 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	30
Likely benign	1
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

728 predictions. Top by Δscore:

Variant	Effect	Δscore
2:232634007:G:GG	donor_gain	1.0000
2:232662908:G:GT	donor_gain	1.0000
2:232662935:C:G	donor_gain	1.0000
2:232662947:G:GT	donor_gain	1.0000
2:232662947:G:T	donor_gain	1.0000
2:232672304:T:A	acceptor_gain	1.0000
2:232672307:A:AG	acceptor_gain	1.0000
2:232672308:G:GA	acceptor_gain	1.0000
2:232672308:GT:G	acceptor_gain	1.0000
2:232672308:GTT:G	acceptor_gain	1.0000
2:232672308:GTTC:G	acceptor_gain	1.0000
2:232672308:GTTCC:G	acceptor_gain	1.0000
2:232672419:TGCC:T	donor_gain	1.0000
2:232672441:AAGG:A	donor_loss	1.0000
2:232672444:G:A	donor_loss	1.0000
2:232672445:T:G	donor_loss	1.0000
2:232633984:G:GT	donor_gain	0.9900
2:232633991:A:T	donor_gain	0.9900
2:232634003:AACT:A	donor_gain	0.9900
2:232634003:AACTG:A	donor_loss	0.9900
2:232634004:ACT:A	donor_gain	0.9900
2:232634004:ACTG:A	donor_loss	0.9900
2:232634005:CT:C	donor_gain	0.9900
2:232634005:CTGT:C	donor_loss	0.9900
2:232634006:TGTG:T	donor_loss	0.9900
2:232634007:GT:G	donor_loss	0.9900
2:232634008:T:G	donor_loss	0.9900
2:232662791:T:A	acceptor_gain	0.9900
2:232662796:CTGCA:C	acceptor_loss	0.9900
2:232662797:TGCA:T	acceptor_loss	0.9900

AlphaMissense

1570 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:232662843:T:C	L115P	0.991
2:232633999:T:C	F99L	0.989
2:232634001:C:A	F99L	0.989
2:232634001:C:G	F99L	0.989
2:232662891:T:C	L131P	0.989
2:232672309:T:C	F151L	0.987
2:232672311:C:A	F151L	0.987
2:232672311:C:G	F151L	0.987
2:232662856:G:A	M119I	0.984
2:232662856:G:C	M119I	0.984
2:232662856:G:T	M119I	0.984
2:232672432:T:C	F192L	0.984
2:232672434:T:A	F192L	0.984
2:232672434:T:G	F192L	0.984
2:232634000:T:C	F99S	0.983
2:232662847:G:C	K116N	0.983
2:232662847:G:T	K116N	0.983
2:232662883:C:A	H128Q	0.983
2:232662883:C:G	H128Q	0.983
2:232672321:T:C	F155L	0.982
2:232672323:C:A	F155L	0.982
2:232672323:C:G	F155L	0.982
2:232672310:T:C	F151S	0.981
2:232662881:C:G	H128D	0.979
2:232662828:T:A	I110N	0.978
2:232672313:T:C	L152P	0.977
2:232672438:G:C	A194P	0.977
2:232662936:T:A	L146H	0.974
2:232662891:T:A	L131Q	0.973
2:232672330:G:C	A158P	0.971

dbSNP variants (sampled 300 via entrez): RS1000040665 (2:232635072 G>C,T), RS1000117442 (2:232646963 T>C), RS1000129451 (2:232643410 A>G), RS1000141048 (2:232632328 A>T), RS1000238959 (2:232663802 A>G), RS1000262827 (2:232670924 T>C), RS1000286905 (2:232630782 A>G), RS1000317007 (2:232682380 A>G), RS1000334173 (2:232610616 G>A,T), RS1000410847 (2:232643167 A>G), RS1000444337 (2:232649446 T>C), RS1000479538 (2:232647964 G>A), RS1000483506 (2:232636468 G>A), RS1000518893 (2:232680832 T>A,G), RS1000551012 (2:232670772 A>G)

Disease associations

OMIM: gene MIM:611617 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

17 associations (top):

Study	Trait	p-value
GCST001277_12	Liver enzyme levels (gamma-glutamyl transferase)	1.000000e-09
GCST002539_44	Schizophrenia	2.000000e-12
GCST005998_8	Alanine transaminase levels	2.000000e-16
GCST005999_7	Aspartate aminotransferase levels	6.000000e-09
GCST006019_46	Gamma glutamyl transferase levels	5.000000e-16
GCST006803_9	Schizophrenia	4.000000e-16
GCST007201_285	Schizophrenia	6.000000e-09
GCST010002_411	Refractive error	1.000000e-123
GCST010479_63	Coronary artery disease	4.000000e-08
GCST011349_43	Gamma glutamyl transferase levels	6.000000e-14
GCST011352_19	Alanine aminotransferase levels	2.000000e-20
GCST90011898_95	Alanine aminotransferase levels	4.000000e-50
GCST90011899_31	Aspartate aminotransferase levels	2.000000e-23
GCST90013405_68	Liver enzyme levels (alanine transaminase)	5.000000e-53
GCST90013407_14	Liver enzyme levels (gamma-glutamyl transferase)	6.000000e-49
GCST90013663_72	Alanine aminotransferase levels	3.000000e-43
GCST90013664_102	Aspartate aminotransferase levels	4.000000e-17

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004532	serum gamma-glutamyl transferase measurement
EFO:0004736	aspartate aminotransferase measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

67 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	6
sodium arsenite	affects methylation, affects cotreatment, decreases expression, increases abundance, increases expression (+1 more)	4
bisphenol A	decreases expression, decreases methylation	3
Resveratrol	affects cotreatment, decreases expression	2
Benzo(a)pyrene	affects methylation, increases methylation	2
Cisplatin	affects expression, decreases expression	2
Silicon Dioxide	decreases expression, decreases methylation	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
Genistein	affects cotreatment, affects expression, increases expression, increases reaction	2
aristolochic acid I	decreases expression	1
dicrotophos	increases expression	1
2,4,6-tribromophenol	increases expression	1
daidzein	affects cotreatment, affects expression	1
methylmercuric chloride	decreases expression	1
propionaldehyde	increases expression	1
decabromobiphenyl ether	decreases expression	1
daidzin	affects expression, affects cotreatment	1
sulforaphane	decreases expression	1
butyraldehyde	increases expression	1
tetrabromobisphenol A	increases expression	1
tobacco tar	decreases expression	1
manganese chloride	decreases expression, increases abundance, affects cotreatment	1
benzo(e)pyrene	decreases methylation	1
potassium chromate(VI)	increases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	decreases expression, affects cotreatment	1
genistin	affects cotreatment, affects expression	1
pentanal	increases expression	1
cordycepin	decreases expression	1
perfluorooctane sulfonic acid	decreases expression	1
glycitein	affects cotreatment, affects expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.